FDA is convening a one-day virtual public workshop on May 18, 2026, focused on the development of surrogate endpoints for drugs and biological products intended to treat rare diseases.
FDA is convening a one-day virtual public workshop on May 18, 2026, focused on the development of surrogate endpoints for drugs and biological products intended to treat rare diseases.
No comments yet. Be the first to share your thoughts.